Loading...
XSHE
300003
Market cap4.13bUSD
Dec 05, Last price  
15.83CNY
1D
1.09%
1Q
-15.03%
Jan 2017
-11.71%
IPO
36.94%
Name

Lepu Medical Technology Beijing Co Ltd

Chart & Performance

D1W1MN
XSHE:300003 chart
P/E
118.19
P/S
4.78
EPS
0.13
Div Yield, %
2.99%
Shrs. gr., 5y
0.87%
Rev. gr., 5y
-4.78%
Revenues
6.10b
-23.52%
175,338,190298,984,733393,879,358565,197,407770,100,945919,846,2401,015,920,0791,303,267,8311,668,636,9552,768,717,4633,467,748,2334,537,642,6566,356,304,7927,795,529,3868,038,667,54010,659,734,87510,609,442,0807,979,899,3186,103,269,105
Net income
247m
-80.37%
63,600,462149,725,515201,368,062292,212,135410,482,721473,157,671403,273,290361,645,473423,192,551520,890,606679,255,737899,085,3301,218,692,8991,725,306,1911,801,932,5321,719,324,5782,203,779,3741,258,200,337246,937,715
CFO
735m
-25.82%
58,317,51961,365,102188,594,285239,785,236374,248,775291,197,594264,962,979329,757,071348,316,884436,460,676691,890,147913,132,5411,500,508,9371,990,255,0632,089,699,3043,061,991,8512,790,709,307990,359,814734,643,889
Dividend
Sep 20, 20240.142 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT